Alnylam Pharmace. buy JPMorgan Chase & Co.
Start price
24.03.25
/
50%
€270.10
Target price
24.03.26
€302.97
Performance (%)
-4.18%
Price
15:04
€258.80
This prediction will end soon
Summary
This prediction is currently active. With a performance of -4.18%, the BUY prediction for Alnylam Pharmace. by JPMorgan_Chase___Co_ is down slightly. This prediction currently runs until 24.03.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -4.728% | -4.728% | - |
| iShares Core DAX® | -3,51 % | -8,75 % | -1,00 % |
| iShares Nasdaq 100 | -2,78 % | -0,63 % | 14,22 % |
| iShares Nikkei 225® | -2,04 % | -6,84 % | 24,87 % |
| iShares S&P 500 | -2,60 % | -2,23 % | 9,20 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $328.00 price target on the stock, up previously from $280.00.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€406.80
13.10.25
13.10.25
€407.06
13.10.26
13.10.26
-36.38%
15:04
15:04
